Literature DB >> 25534677

Electrophysiologic findings and long-term outcomes in patients undergoing third or more catheter ablation procedures for atrial fibrillation.

David Lin1, Pasquale Santangeli1, Erica S Zado1, Rupa Bala1, Mathew D Hutchinson1, Michael P Riley1, David S Frankel1, Fermin Garcia1, Sanjay Dixit1, David J Callans1, Francis E Marchlinski1.   

Abstract

INTRODUCTION: Pulmonary vein (PV) status, arrhythmia sources, and outcomes with ≥3 ablation procedures have not been characterized. METHODS AND
RESULTS: All patients with ≥3 procedures were included and underwent antral reisolation of reconnected PVs and ablation of non-PV triggers. Of 2,886 patients who underwent PVI, 181 (6%) had more than 2 ablation procedures (3 procedures in 146 and ≥4 procedures in 35). In 12 patients, the clinical arrhythmia was other than AF. Of the remaining 169 patients, 69 (41%) had 4 reconnected PVs, 27 (16%) had 3, 31 (18%) had 2, and 29 (17%) had 1. Only 13 (8%) had all PVs still isolated. Provocative techniques in 127 patients initiated PV triggers in 92 patients, including AF or PV atrial tachycardia in 64 (50%), and reproducible PV APDs in 28 (22%). Thirty-six (20%) had a new non-PV trigger targeted. At a mean of 36 months (12-119 months) after last procedure, 63 patients (47%) had no AF off antiarrhythmic drugs (AAD); 28 (21%) had no AF with AAD; and 18 (13%) had rare AF with good symptom control; 26 patients (19%) had recurrent AF.
CONCLUSIONS: At time of third or greater AF ablation, PV reconnection is the rule (92%) and PV triggers initiating AF can be demonstrated. Following repeat PVI and targeting non-PV triggers, 81% of patients had clinical AF control. Our findings suggest that PV reisolation and attempts to identify and eliminate non-PV triggers are effective and support the role of multiple repeat procedures for AF recurrence.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; catheter ablation; pulmonary vein isolation; reconnection; repeat ablation

Mesh:

Substances:

Year:  2015        PMID: 25534677     DOI: 10.1111/jce.12603

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  12 in total

1.  Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy.

Authors:  Ki-Hun Kim; Sanghamitra Mohanty; Prasant Mohanty; Chintan Trivedi; Eli Hamilton Morris; Pasquale Santangeli; Rong Bai; Amin Al-Ahmad; John David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Shane Bailey; Patrick M Hranitzky; Jason Zagrodzky; Soo G Kim; Luigi Di Biase; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2017-03-07       Impact factor: 1.900

2.  Pulmonary vein reconnection following catheter ablation of atrial fibrillation using the second-generation cryoballoon versus open-irrigated radiofrequency: results of a multicenter analysis.

Authors:  Arash Aryana; Sheldon M Singh; Giacomo Mugnai; Carlo de Asmundis; Marcin Kowalski; Deep K Pujara; Andrew I Cohen; Steve K Singh; Charles E Fuenzalida; Nelson Prager; Mark R Bowers; Padraig Gearoid O'Neill; Pedro Brugada; André d'Avila; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2016-07-30       Impact factor: 1.900

3.  Dose-dependent pulmonary vein reconnection in response to adenosine: relevance of atrioventricular block during infusion.

Authors:  Suraj Kapa; Ammar Killu; Abhishek Deshmukh; Siva K Mulpuru; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2016-05-28       Impact factor: 1.900

Review 4.  Recurrent Atrial Fibrillation After Catheter Ablation: Considerations For Repeat Ablation And Strategies To Optimize Success.

Authors:  Andrew E Darby
Journal:  J Atr Fibrillation       Date:  2016-06-30

5.  The incremental benefit of non-pulmonary vein left atrial ablation in patients undergoing a repeat persistent atrial fibrillation ablation procedure.

Authors:  Gustavo R Goldenberg; Masa Ono; Arash Aryana; Andre d'Avila; Eduardo B Saad; Steve K Singh; Sheldon M Singh
Journal:  J Interv Card Electrophysiol       Date:  2016-10-20       Impact factor: 1.900

Review 6.  Very Long-Term Results Of Atrial Fibrillation Ablation Confirm That This Therapy Is Really Effective.

Authors:  Cristina Tutuianu; Judit Szilagy; Robert Pap; László Sághy
Journal:  J Atr Fibrillation       Date:  2015-08-31

7.  Predictors of long-term outcome in patients undergoing a first repeat ablation consisting solely of re-isolation of reconnected pulmonary veins.

Authors:  Juan-Pablo Abugattas; Bruno Schwagten; Jeroen De Cocker; Hugo-Enrique Coutiño; Francesca Salghetti; Varnavas Varnavas; Erwin Ströker; Juan Sieira; Michael Wolf; Pedro Brugada; Carlo de Asmundis; Gian-Battista Chierchia; Yves De Greef
Journal:  J Atr Fibrillation       Date:  2019-02-28

8.  Repeat pulmonary vein isolation with or without FIRM-guided ablation for recurrent atrial fibrillation with pulmonary vein reconnection.

Authors:  Graham Peigh; Jeremiah Wasserlauf; Rachel M Kaplan; Ansel P Amaral; Amar Trivedi; Alexandru B Chicos; Rishi Arora; Susan Kim; Albert Lin; Nishant Verma; Bradley P Knight; Rod S Passman
Journal:  J Cardiovasc Electrophysiol       Date:  2020-03-09       Impact factor: 2.942

Review 9.  Mechanisms and clinical significance of early recurrences of atrial arrhythmias after catheter ablation for atrial fibrillation.

Authors:  Jackson J Liang; Sanjay Dixit; Pasquale Santangeli
Journal:  World J Cardiol       Date:  2016-11-26

10.  Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial.

Authors:  Habib Rehman Khan; Ines Kralj-Hans; Shouvik Haldar; Toufan Bahrami; Jonathan Clague; Anthony De Souza; Darrel Francis; Wajid Hussain; Julian Jarman; David Gareth Jones; Neeraj Mediratta; Raad Mohiaddin; Tushar Salukhe; Simon Jones; Joanne Lord; Caroline Murphy; Joanna Kelly; Vias Markides; Dhiraj Gupta; Tom Wong
Journal:  Trials       Date:  2018-02-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.